Bio-Rad Reports Third-Quarter 2015 Financial Results
HERCULES, CA--(Marketwired - November 03, 2015) - Bio-Rad Laboratories, Inc. (NYSE: BIO) (NYSE: BIO.B), a global provider of life science research and clinical diagnostic products, announced financial results today for the third quarter ended September 30, 2015.
Third-quarter reported revenues were $470.0 million, a decrease of 11.4% compared to $530.6 million reported for the third quarter of 2014. On a currency-neutral basis, quarterly revenues decreased 2.2% compared to the same period last year. Third-quarter gross margin increased to 56.1% compared to 54.4% during the same quarter in 2014. The year-over-year increase in gross margin in the third quarter compared to the same period last year was primarily due to a more favorable product mix as well as the consolidation and closure of certain facilities and product lines in 2014.
Net income for the third quarter was $17.4 million, or $0.59 per share on a fully diluted basis, compared to $11.5 million, or $0.39 per share during the same period last year. The increase in net income for the third quarter of 2015 was primarily the result of the absence of a nonrecurring expense of $12.1 million.
Year-to-date revenues were $1.45 billion, a decrease of 8.1% compared to $1.58 billion reported in the first three quarters of 2014. Adjusting for the impact of currency, year-to-date revenue growth for the first nine months of 2015 was 1.2%.
Year-to-date net income for the first three quarters of 2015 was $63.6 million, or $2.17 per share on a fully diluted basis, compared to $49.8 million, or $1.71 per share reported during the same period in 2014. The year-over-year increase of net income resulted primarily from several discrete items including the absence of nonrecurring expenses of $20.1 million accrued during the same period last year. This was partially offset by an increase of $7.6 million of expense reflecting the revaluation of contingent consideration for certain acquisitions, $3.3 million of bad debt expense, and a one-time distributor termination expense of $1.9 million. The effective income tax rate for the first nine months of 2015 was 31% compared to the tax rate of 42% during the same period in 2014. The lower tax rate in 2015 was primarily due to a decrease in tax reserves as a result of the expiration of statutes of limitation. The higher tax rate in 2014 was primarily due to losses incurred in foreign jurisdictions and nondeductible penalties.
Life Science
The Life Science segment net sales for the third quarter were $150.4 million, a decrease of 13.0% compared to the same period last year. On a currency-neutral basis, the Life Science segment sales were down 5.9% compared to the third quarter of 2014. The currency neutral sales decrease was somewhat offset by growth in Droplet Digital™ PCR products, the V3 Western Workflow™ western blotting portfolio, and iQ-Check® food science products. The currency neutral sales decrease was primarily in the U.S. and Asia, while sales in Europe had modest growth.
Clinical Diagnostics
Reported net sales for the Clinical Diagnostics segment in the third quarter were $316.2 million, a decrease of 10.9% compared to the third quarter in 2014. On a currency-neutral basis, the Clinical Diagnostics segment sales were relatively flat, decreasing 0.5% versus the same period last year. The segment achieved good overall sales growth in North America. Sales of quality control products were strong worldwide. Offsetting this was continued weakness in European markets, which are still experiencing consolidation and pricing pressures. In July, Bio-Rad announced that it had received U.S. Food and Drug Administration pre-market approval to offer its BioPlex® 2200 HIV Ag-Ab assay, the company's 5th generation HIV diagnostic test. Also during the quarter, Bio-Rad introduced the IH-500, a fully automated random access system for blood typing and screening for small and medium-size transfusion medicine laboratories. The instrument is available in Europe, Asia, Africa, Australia, and Latin America.
Management will discuss these results in a conference call at 2 PM Pacific Time (5 PM Eastern Time) November 3, 2015. Interested parties may access the call at 877-311-4349 within the U.S. or 720-634-9933 outside the U.S., passcode: 55492775. You may also listen to the conference call live via a webcast that is available on the "Investor Relations" section of our website under "Quarterly Results" at www.bio-rad.com. The webcast will be available for up to a year.
About Bio-Rad
Bio-Rad Laboratories, Inc. (NYSE: BIO) (NYSE: BIO.B) develops, manufactures, and markets a broad range of innovative products and solutions for the life science research and clinical diagnostic markets. The company is renowned for its commitment to quality and customer service among university and research institutions, hospitals, public health and commercial laboratories, as well as the biotechnology, pharmaceutical, and food safety industries. Founded in 1952, Bio-Rad is based in Hercules, California, and serves more than 100,000 research and healthcare industry customers through its global network of operations. The company employs more than 7,600 people worldwide and had revenues exceeding $2.1 billion in 2014. For more information, please visit www.bio-rad.com.
This release may be deemed to contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make regarding our release of new products, sales by region and future financial performance. Forward-looking statements generally can be identified by the use of forward-looking terminology such as, "believe," "expect," "anticipate," "may," "will," "intend," "estimate," "continue," or similar expressions or the negative of those terms or expressions, although not all forward-looking statements contain these words. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. These risks and uncertainties include foreign currency exchange fluctuations, our ability to develop and market new or improved products, difficulties in implementing our global enterprise resource planning system, supply chain issues, our ability to compete effectively, product quality and liability issues, reductions in government funding or capital spending of our customers, international legal and regulatory risks, recent changes to our global organizational structure and executive management team, changes in the healthcare industry, global economic conditions, and natural disasters and other catastrophic events beyond our control. For further information regarding the Company's risks and uncertainties, please refer to the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operation" in the Company's public reports filed with the Securities and Exchange Commission (the "SEC"), including the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2014 and its Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2015 to be filed with the SEC. The Company cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. Bio-Rad Laboratories, Inc. disclaims any obligation to update these forward-looking statements.
Bio-Rad Laboratories, Inc.
Condensed Consolidated Statements of Income
(in thousands, except per share data)
(UNAUDITED)
Three Months Ended Nine Months Ended
September 30, September 30,
-------------------- ----------------------
2015 2014 2015 2014
--------- --------- ---------- ----------
Net sales $ 469,961 $ 530,644 $1,448,884 $1,576,820
Cost of goods sold 206,509 242,068 635,729 715,713
--------- --------- ---------- ----------
Gross profit 263,452 288,576 813,155 861,107
Selling, general and
administrative expense 187,445 202,550 568,845 600,663
Research and development
expense 43,336 52,786 137,085 161,046
--------- --------- ---------- ----------
Income from operations 32,671 33,240 107,225 99,398
Interest expense 5,822 7,710 15,658 17,131
Foreign currency exchange
losses (gains), net 2,166 3,667 8,910 6,118
Other (income) expense, net (732) (613) (8,992) (9,662)
--------- --------- ---------- ----------
Income before income taxes 25,415 22,476 91,649 85,811
Provision for income taxes (8,045) (10,967) (28,038) (36,003)
--------- --------- ---------- ----------
Net income $ 17,370 $ 11,509 $ 63,611 $ 49,808
========= ========= ========== ==========
Basic earnings per share:
Net income per basic share $ 0.59 $ 0.40 $ 2.18 $ 1.73
========= ========= ========== ==========
Weighted average common
shares - basic 29,195 28,884 29,141 28,834
========= ========= ========== ==========
Diluted earnings per share:
Net income per diluted share $ 0.59 $ 0.39 $ 2.17 $ 1.71
========= ========= ========== ==========
Weighted average common
shares - diluted 29,439 29,141 29,372 29,097
========= ========= ========== ==========
Bio-Rad Laboratories, Inc.
Condensed Consolidated Balance Sheets
(In thousands)
September 30, December 31,
2015 2014
------------- ------------
(UNAUDITED)
Current assets:
Cash and cash equivalents $ 507,329 $ 413,251
Short-term investments 278,749 284,384
Accounts receivable, net 341,548 377,640
Inventories, net 512,736 470,997
Other current assets 154,054 170,095
------------- ------------
Total current assets 1,794,416 1,716,367
Property, plant and equipment, net 433,822 428,836
Goodwill, net 503,588 500,441
Purchased intangibles, net 225,020 254,228
Other investments 663,533 389,309
Other assets 46,017 52,097
------------- ------------
Total assets $ 3,666,396 $ 3,341,278
============= ============
Current liabilities:
Accounts payable, accrued payroll and employee
benefits $ 268,228 $ 282,034
Current maturities of long-term debt 379 265
Income and other taxes payable 22,621 35,165
Other current liabilities 144,007 129,297
------------- ------------
Total current liabilities 435,235 446,761
Long-term debt, net of current maturities 435,728 435,710
Other long-term liabilities 365,704 273,652
------------- ------------
Total liabilities 1,236,667 1,156,123
------------- ------------
Total stockholders' equity 2,429,729 2,185,155
------------- ------------
Total liabilities and stockholders' equity $ 3,666,396 $ 3,341,278
============= ============
Bio-Rad Laboratories, Inc.
Condensed Consolidated Statements of Cash Flows
(In thousands)
(UNAUDITED)
Nine Months Ended
September 30,
2015 2014
----------- -----------
Cash flows from operating activities:
Cash received from customers $ 1,443,672 $ 1,613,723
Cash paid to suppliers and employees (1,278,255) (1,352,654)
Interest paid, net (9,620) (10,757)
Income tax payments, net (15,646) (31,105)
Other operating activities 10,107 13,889
----------- -----------
Net cash provided by operating activities 150,258 233,096
Cash flows from investing activities:
Payments for acquisitions and long-term
investments (3,490) (43,645)
Other investing activities (79,601) (97,422)
----------- -----------
Net cash used in investing activities (83,091) (141,067)
Cash flows from financing activities:
Payments on long-term borrowings (206) (181)
Other financing activities 5,059 8,245
----------- -----------
Net cash provided by financing activities 4,853 8,064
Effect of foreign exchange rate changes on cash 22,058 (7,051)
----------- -----------
Net increase in cash and cash equivalents 94,078 93,042
Cash and cash equivalents at beginning of period 413,251 331,551
----------- -----------
Cash and cash equivalents at end of period $ 507,329 $ 424,593
=========== ===========
Reconciliation of net income provided by operating
activities:
Net income $ 63,611 $ 49,808
Adjustments to reconcile net income to net cash
provided by operating activities:
Depreciation and amortization 97,970 110,129
Changes in working capital (15,364) 61,772
Other 4,041 11,387
----------- -----------
Net cash provided by operating activities $ 150,258 $ 233,096
=========== ===========
Investor and Financial Contacts:
Bio-Rad Laboratories, Inc.
Christine Tsingos
Executive Vice President and Chief Financial Officer
Ron Hutton
Vice President, Treasurer
510-724-7000
Email Contact
Help employers find you! Check out all the jobs and post your resume.